Italian company Diasorin – a world leader in laboratory diagnostics – has been firmly established in the United States for years and in 2021 launched a €1.8 billion takeover bid to acquire Texas-based Luminex. It now intends to invest an additional €500 million to expand its production capacity in the United States and Europe. The major challenge, highlighted by the pandemic, is to decentralize diagnostics. "These are complex programs”, CEO Carlo Rosa told Corriere della Sera, "in which we have already invested approximately €100 million. We are already in discussions with numerous Italian hospitals on the possibilities of diffusing innovative diagnostic technology across multiple departments. In the United States, this technique is far more advanced; our equipment is already in hospitals, but we hope to eventually deliver them directly to doctors".